Novel allosteric modulators of G protein-coupled receptors

Journal of Biological Chemistry

Volumn 290, Issue 32, 2015, Pages 19478-19488

  Gentry, Patrick R ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SIGNAL TRANSDUCTION;

ALLOSTERIC MODULATORS; ALLOSTERIC PROTEINS; ALLOSTERIC SITE; ALLOSTERY; BIOLOGICAL CHARACTERIZATION; CHEMICAL PROBES; G PROTEIN COUPLED RECEPTORS; STRUCTURAL BIOLOGY;

PROTEINS;

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; AROMATIC AMINO ACID; AUTOANTIBODY; BENZIMIDAZOLE DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; DOPAMINE 2 RECEPTOR; ENDOTHELIN A RECEPTOR; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR ALLOSTERIC MODULATOR; GEVOKIZUMAB; GONADORELIN RECEPTOR; KT 5720; KT 5823; LIGAND; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR ACCESSORY PROTEIN; MUSCARINIC M2 RECEPTOR; RECEPTOR ACTIVITY MODIFYING PROTEIN; SEROTONIN 4 RECEPTOR; SMOOTHENED PROTEIN; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; PROTEIN BINDING;

ALLOSTERISM; BINDING SITE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HISTORY; HUMAN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HISTORY, 21ST CENTURY; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939164437     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R115.662759     Document Type: Short Survey

References (100)

1. Fredriksson, R., Lagerström, M. C., Lundin, L.-G., and Schiöth, H. B. (2003) The G-protein-coupled receptors in the human genome form five main families: phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272
2. Kenakin, T., and Miller, L. J. (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304
3. Oldham, W. M., and Hamm, H. E. (2006) Structural basis of function in heterotrimeric G proteins. Q. Rev. Biophys. 39, 117-166
4. Rask-Andersen, M., Almén, M. S., and Schiöth, H. B. (2011) Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590
5. Conn, P. J., Lindsley, C. W., Meiler, J., and Niswender, C. M. (2014) Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat. Rev. Drug Discov. 13, 692-708
6. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L.(2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996
7. Monod, J., Changeux, J.-P., and Jacob, F. (1963) Allosteric proteins and cellular control systems. J. Mol. Biol. 6, 306-329
8. Christopoulos, A., and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374
9. Fenton, A. W. (2008) Allostery: an illustrated definition for the "second secret of life." Trends Biochem. Sci. 33, 420-425
10. Monod, J., Wyman, J., and Changeux, J.-P. (1965) On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12, 88-118
11. Koshland, D. E., Jr., Némethy, G., and Filmer, D. (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5, 365-385
12. Motlagh, H. N., Wrabl, J. O., Li, J., and Hilser, V. J. (2014) The ensemble nature of allostery. Nature 508, 331-339
13. Canals, M., Sexton, P. M., and Christopoulos, A. (2011) Allostery in GPCRs: "MWC" revisited. Trends Biochem. Sci. 36, 663-672
14. Conn, P. J., Christopoulos, A., and Lindsley, C. W. (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41-54
15. Christopoulos, A., Changeux, J.-P., Catterall, W. A., Fabbro, D., Burris, T. P., Cidlowski, J. A., Olsen, R. W., Peters, J. A., Neubig, R. R., Pin, J.-P., Sexton, P. M., Kenakin, T. P., Ehlert, F. J., Spedding, M., and Langmead, C. J. (2014) International union of basic and clinical pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev. 66, 918-947
16. Mohr, K., Tränkle, C., Kostenis, E., Barocelli, E., De Amici, M., and Holzgrabe, U. (2010) Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol. 159, 997-1008
17. Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., and Christopoulos, A. (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312-29321
18. Valant, C., Robert Lane, J., Sexton, P. M., and Christopoulos, A. (2012) The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52, 153-178
19. Lazareno, S., Dolezal, V., Popham, A., and Birdsall, N. J. M. (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65, 257-266
20. Christopoulos, A. (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198-210
21. Kenakin, T. (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4, 919-927
22. Wootten, D., Christopoulos, A., and Sexton, P. M. (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug. Discov. 12, 630-644
23. Leach, K., Sexton, P. M., and Christopoulos, A. (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382-389
24. Kenakin, T., and Christopoulos, A. (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216
25. Valant, C., May, L. T., Aurelio, L., Chuo, C. H., White, P. J., Baltos, J.-A., Sexton, P. M., Scammells, P. J., and Christopoulos, A. (2014) Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc. Natl. Acad. Sci. U.S.A. 111, 4614-4619
26. van der Westhuizen, E. T., Valant, C., Sexton, P. M., and Christopoulos, A. (2015) Endogenous allosteric modulators of G protein-coupled receptors. J. Pharmacol. Exp. Ther. 353, 246-260
27. Luttrell, L. M., Ferguson, S. S., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G., and Lefkowitz, R. J. (1999) β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661
28. Lefkowitz, R. J., and Shenoy, S. K. (2005) Transduction of receptor signals by β-arrestins. Science 308, 512-517
29. Luttrell, L. M., and Gesty-Palmer, D. (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62, 305-330
30. Reiter, E., Ahn, S., Shukla, A. K., and Lefkowitz, R. J. (2012) Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179-197
31. Gurevich, V. V., Pals-Rylaarsdam, R., Benovic, J. L., Hosey, M. M., and Onorato, J. J. (1997) Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J. Biol. Chem. 272, 28849-28852
32. Galandrin, S., Oligny-Longpré, G., Bonin, H., Ogawa, K., Galés, C., and Bouvier, M. (2008) Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the β1-adrenergic receptor. Mol. Pharmacol. 74, 162-172
33. Tang, W., Strachan, R. T., Lefkowitz, R. J., and Rockman, H. A. (2014) Allosteric modulation of β-arrestin-biased angiotensin II type 1 receptor signaling by membrane stretch. J. Biol. Chem. 289, 28271-28283
34. Milligan, G. (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14
35. Conigrave, A. D., Quinn, S. J., and Brown, E. M. (2000) L-Amino acid sensing by the extracellular Ca2+-sensing receptor. Proc. Natl. Acad. Sci. U.S.A. 97, 4814-4819
36. Zhang, Z., Qiu, W., Quinn, S. J., Conigrave, A. D., Brown, E. M., and Bai, M. (2002) Three adjacent serines in the extracellular domains of the CaR are required for L-amino acid-mediated potentiation of receptor function. J. Biol. Chem. 277, 33727-33735
37. Mun, H. C., Culverston, E. L., Franks, A. H., Collyer, C. A., Clifton-Bligh, R. J., and Conigrave, A. D. (2005) A double mutation in the extracellular Ca2+-sensing receptor's Venus flytrap domain that selectively disables L-amino acid sensing. J. Biol. Chem. 280, 29067-29072
38. Ogawa, H., Qiu, Y., Philo, J. S., Arakawa, T., Ogata, C. M., and Misono, K. S. (2010) Reversibly bound chloride in the atrial natriuretic peptide receptor hormone-binding domain: possible allosteric regulation and a conserved structural motif for the chloride-binding site. Protein Sci. 19, 544-557
39. Selvam, C., Oueslati, N., Lemasson, I. A., Brabet, I., Rigault, D., Courtiol, T., Cesarini, S., Triballeau, N., Bertrand, H. O., Goudet, C., Pin, J.-P., and Acher, F. C. (2010) A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J. Med. Chem. 53, 2797-2813
40. Acher, F. C., Selvam, C., Pin, J.-P., Goudet, C., and Bertrand, H. O. (2011) A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design. Neuropharmacology 60, 102-107
41. Gregory, K. J., Sexton, P. M., and Christopoulos, A. (2007) Allosteric modulation of muscarinic acetylcholine receptors. Curr. Neuropharmacol. 5, 157-167
42. Lüllmann, H., Ohnesorge, F. K., Schauwecker, G. C., and Wassermann, O. (1969) Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. Eur. J. Pharmacol. 6, 241-247
43. Clark, A. L., and Mitchelson, F. (1976) The inhibitory effect of gallamine on muscarinic receptors. Br. J. Pharmacol. 58, 323-331
44. Stockton, J. M., Birdsall, N. J., Burgen, A. S., and Hulme, E. C. (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23, 551-557
45. Proska, J., and Tucek, S. (1994) Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 45, 709-717
46. Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J. M., Thompson, R. C., Christopoulos, A., Lazareno, S., Birdsall, N. J. M., Bymaster, F. P., and Felder, C. C. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 105, 10978-10983
47. Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., and Christopoulos, A. (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869
48. Steinfeld, T., Mammen, M., Smith, J. A. M., Wilson, R. D., and Jasper, J. R. (2007) A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol. Pharmacol. 72, 291-302
49. Christopoulos, A., Lanzafame, A., and Mitchelson, F. (1998) Allosteric interactions at muscarinic cholinoceptors. Clin. Exp. Pharmacol. Physiol. 25, 185-194
50. Ellis, J., and Seidenberg, M. (2000) Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. Mol. Pharmacol. 58, 1451-1460
51. Lazareno, S., Gharagozloo, P., Kuonen, D., Popham, A., and Birdsall, N. J. (1998) Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol. Pharmacol. 53, 573-589
52. Lazareno, S., Popham, A., and Birdsall, N. J. (2000) Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-3H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol. Pharmacol. 58, 194-207
53. Lazareno, S., Popham, A., and Birdsall, N. J. M. (2002) Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol. Pharmacol. 62, 1492-1505
54. Lanzafame, A. A., Sexton, P. M., and Christopoulos, A. (2006) Interaction studies of multiple binding sites on M4 muscarinic acetylcholine receptors. Mol. Pharmacol. 70, 736-746
55. Sullivan, S. K., Brown, M. S., Gao, Y., Loweth, C. J., Lio, F. M., Crowe, P. D., Struthers, R. S., and Betz, S. F. (2006) Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists. Biochemistry 45, 15327-15337
56. Heitman, L. H., Ye, K., Oosterom, J., and Ijzerman, A. P. (2008) Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol. Pharmacol. 73, 1808-1815
57. Nicholls, D. J., Tomkinson, N. P., Wiley, K. E., Brammall, A., Bowers, L., Grahames, C., Gaw, A., Meghani, P., Shelton, P., Wright, T. J., and Mallinder, P. R. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol. Pharmacol. 74, 1193-1202
58. Andrews, G., Jones, C., and Wreggett, K. A. (2008) An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol. Pharmacol. 73, 855-867
59. Salchow, K., Bond, M. E., Evans, S. C., Press, N. J., Charlton, S. J., Hunt, P. A., and Bradley, M. E. (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharmacol. 159, 1429-1439
60. Hollenberg, M. D., Saifeddine, M., Sandhu, S., Houle, S., and Vergnolle, N. (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br. J. Pharmacol. 143, 443-454
61. Kaneider, N. C., Agarwal, A., Leger, A. J., and Kuliopulos, A. (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat. Med. 11, 661-665
62. Bortolato, A., Doré, A. S., Hollenstein, K., Tehan, B. G., Mason, J. S., and Marshall, F. H. (2014) Structure of Class B GPCRs: new horizons for drug discovery. Br. J. Pharmacol. 171, 3132-3145
63. Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., Xie, X., Nan, F., Young, A. A, and Wang, M.-W. (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. U.S.A. 104, 943-948
64. Nolte, W. M., Fortin, J.-P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., and Carpino, P. A. (2014) A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat. Chem. Biol. 10, 629-631
65. Gregory, K. J., Dong, E. N., Meiler, J., and Conn, P. J. (2011) Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60, 66-81
66. Gregory, K. J., and Conn, P. J. (2015) Molecular insights into metabotropic glutamate receptor allosteric modulation. Mol. Pharmacol. 88, 188-202
67. O'Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S. N., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H. J., Rowe, B., Sur, C., Duggan, M. E., Pettibone, D. J., Conn, P. J., and Williams, D. L. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 309, 568-577
68. Chen, Y., Nong, Y., Goudet, C., Hemstapat, K., de Paulis, T., Pin, J.-P., and Conn, P. J. (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 71, 1389-1398
69. Hammond, A. S., Rodriguez, A. L., Townsend, S. D., Niswender, C. M., Gregory, K. J., Lindsley, C. W., and Conn, P. J. (2010) Discovery of a novel chemical class of mGlu5 allosteric ligands with distinct modes of pharmacology. ACS Chem. Neurosci. 1, 702-716
70. Rodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., Blatt, T. N., Jadhav, S., Menon, U. N., Vinson, P. N., Rook, J. M., Stauffer, S. R., Niswender, C. M., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 78, 1105-1123
71. Lamb, J. P., Engers, D. W., Niswender, C. M., Rodriguez, A. L., Venable, D. F., Conn, P. J., and Lindsley, C. W. (2011) Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Bioorg. Med. Chem. Lett. 21, 2711-2714
72. Noetzel, M. J., Rook, J. M., Vinson, P. N., Cho, H. P., Days, E., Zhou, Y., Rodriguez, A. L., Lavreysen, H., Stauffer, S. R., Niswender, C. M., Xiang, Z., Daniels, J. S., Jones, C. K., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol. Pharmacol. 81, 120-133
73. Zhao, Z., Wisnoski, D. D., O'Brien, J. A., Lemaire, W., Williams, D. L., Jr., Jacobson, M. A., Wittman, M., Ha, S. N., Schaffhauser, H., Sur, C., Pettibone, D. J., Duggan, M. E., Conn, P. J., Hartman, G. D., and Lindsley, C. W. (2007) Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem. Lett. 17, 1386-1391
74. Chen, Y., Goudet, C., Pin, J.-P., and Conn, P. J. (2008) N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 73, 909-918
75. Zhang, Y., Rodriguez, A. L., and Conn, P. J. (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 315, 1212-1219
76. Noetzel, M. J., Gregory, K. J., Vinson, P. N., Manka, J. T., Stauffer, S. R., Lindsley, C. W., Niswender, C. M., Xiang, Z., and Conn, P. J. (2013) A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol. Pharmacol. 83, 835-847
77. Generoso, S. F., Giustiniano, M., La Regina, G., Bottone, S., Passacantilli, S., Di Maro, S., Cassese, H., Bruno, A., Mallardo, M., Dentice, M., Silvestri, R., Marinelli, L., Sarnataro, D., Bonatti, S., Novellino, E., and Stornaiuolo, M. (2015) Pharmacological folding chaperones act as allosteric ligands of Frizzled4. Nat. Chem. Biol. 11, 280-286
78. Wang, C., Wu, H., Evron, T., Vardy, E., Han, G. W., Huang, X.-P., Hufeisen, S. J., Mangano, T. J., Urban, D. J., Katritch, V., Cherezov, V., Caron, M. G., Roth, B. L., and Stevens, R. C. (2014) Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat. Commun. 5, 4355
79. Bhaskar, V., Goldfine, I. D., Bedinger, D. H., Lau, A., Kuan, H. F., Gross, L. M., Handa, M., Maddux, B. A., Watson, S. R., Zhu, S., Narasimha, A. J., Levy, R., Webster, L., Wijesuriya, S. D., Liu, N., Wu, X., Chemla-Vogel, D., Tran, C., Lee, S. R., Wong, S., Wilcock, D., White, M. L., and Corbin, J. A. (2012) A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 61, 1263-1271
80. Bhaskar, V., Lau, A., Goldfine, I. D., Narasimha, A. J., Gross, L. M., Wong, S., Cheung, B., White, M. L., and Corbin, J. A. (2013) XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity. Diabetes Obes. Metab. 15, 272-275
81. Roell, M. K., Issafras, H., Bauer, R. J., Michelson, K. S., Mendoza, N., Vanegas, S. I., Gross, L. M., Larsen, P. D., Bedinger, D. H., Bohmann, D. J., Nonet, G. H., Liu, N., Lee, S. R., Handa, M., Kantak, S. S., Horwitz, A. H., Hunter, J. J., Owyang, A. M., Mirza, A. M., Corbin, J. A., and White, M. L. (2010) Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1β activity. J. Biol. Chem. 285, 20607-20614
82. Issafras, H., Corbin, J. A., Goldfine, I. D., and Roell, M. K. (2014) Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J. Pharmacol. Exp. Ther. 348, 202-215
83. Schultz Kirkegaard, H., and Valentin, F. (2014) Academic drug discovery centres: the economic and organisational sustainability of an emerging model. Drug Discov. Today 19, 1699-1710
84. Nicolaou, K. C. (2014) Advancing the drug discovery and development process. Angew Chem. Int. Ed. Engl. 53, 9128-9140
85. Bouvier, M., Heveker, N., Jockers, R., Marullo, S., and Milligan, G. (2007) BRET analysis of GPCR oligomerization: newer does not mean better. Nat. Methods 4, 3-4; author reply 4, 10.1038/nmeth0107-3
86. Huber, T., and Sakmar, T. P. (2014) Chemical Biology Methods for Investigating G Protein-Coupled Receptor Signaling. Chem. Biol. 21, 1224-1237
87. Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J., and Lindsley, C. W. (2011) "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 50, 2403-2410
88. Davie, B. J., Valant, C., White, J. M., Sexton, P. M., Capuano, B., Christopoulos, A., and Scammells, P. J. (2014) Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M1 muscarinic acetylcholine receptor. J. Med. Chem. 57, 5405-5418
89. Pittolo, S., Gómez-Santacana, X., Eckelt, K., Rovira, X., Dalton, J., Goudet, C., Pin, J.-P., Llobet, A., Giraldo, J., Llebaria, A., and Gorostiza, P. (2014) An allosteric modulator to control endogenous G protein-coupled receptors with light. Nat. Chem. Biol. 10, 813-815
90. Wootten, D., Savage, E. E., Willard, F. S., Bueno, A. B., Sloop, K. W., Christopoulos, A., and Sexton, P. M. (2013) Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol. Pharmacol. 83, 822-834
91. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745
92. Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., Zhang, W., Xie, X., Yang, H., Jiang, H., Cherezov, V., Liu, H., Stevens, R. C., Zhao, Q., and Wu, B. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390
93. Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K. Y., Doré, A. S., Jazayeri, A., Cooke, R. M., Weir, M., and Marshall, F. H. (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438-443
94. Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katritch, V., Meiler, J., Cherezov, V., Conn, P. J., and Stevens, R. C. (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344, 58-64
95. Doré, A. S., Okrasa, K., Patel, J. C., Serrano-Vega, M., Bennett, K., Cooke, R. M., Errey, J. C., Jazayeri, A., Khan, S., Tehan, B., Weir, M., Wiggin, G. R., and Marshall, F. H. (2014) Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511, 557-562
96. Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T. A., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal structure of the β2-adrenergic receptor-Gs protein complex. Nature 477, 549-555
97. Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., and Kobilka, B. K. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101-106
98. Dror, R. O., Green, H. F., Valant, C., Borhani, D. W., Valcourt, J. R., Pan, A. C., Arlow, D. H., Canals, M., Lane, J. R., Rahmani, R., Baell, J. B., Sexton, P. M., Christopoulos, A., and Shaw, D. E. (2013) Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503, 295-299
99. Didenko, T., Liu, J. J., Horst, R., Stevens, R. C., and Wüthrich, K. (2013) Fluorine-19 NMR of integral membrane proteins illustrated with studies of GPCRs. Curr. Opin. Struct. Biol. 23, 740-747
100. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., and Wüthrich, K. (2012) Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 335, 1106-1110